NovoCureBSP:N2VC34 46 EV-to-FCF is 0.73 as of Jun. 25, 2026. GuruFocus rates BSP:N2VC34 with a GF Score™ of 46/100 and a GF Value™ of R$8.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 420 Medical Devices & Instruments companies, NovoCure ranks worse than 238095% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NovoCure's Enterprise Value is R$-190 Mil.
NovoCure's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was R$-261 Mil. Therefore, NovoCure's EV-to-FCF for today is 0.73.
The historical rank and industry rank for NovoCure's EV-to-FCF or its related term are showing as below:
BSP:N2VC34'
s EV-to-FCF Range Over the Past 10 Years
Min: -1743.95 Med: -9.84 Max: 1587.78
Current: -31.37
During the past 13 years, the highest EV-to-FCF of NovoCure was 1587.78. The lowest was -1743.95. And the median was -9.84.
BSP:N2VC34's EV-to-FCF is ranked worse than 100% of 420
companies
in the Medical Devices & Instruments industry
Industry Median: 22.865
vs BSP:N2VC34: -31.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NovoCure's share price for today is R$7.08.
NovoCure's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-8.208.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
NovoCure EV-to-FCF Related Terms
NovoCure EV-to-FCF Historical Data
* Premium members only.
The historical data trend for NovoCure's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:N2VC34 vs NEOG, ESTA, AXGN: EV-to-FCF Comparison
For the Medical Devices subindustry, NovoCure's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where NovoCure's EV-to-FCF falls into.
NovoCure's current Enterprise Value is R$-190 Mil.
NovoCure's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-261 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure (BSP:N2VC34) has a EV-to-FCF of 0.73 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NovoCure and its competitors. According to the industry distribution chart, NovoCure ranks #999999 out of 420 companies in the Medical Devices & Instruments industry.
Is NovoCure's EV-to-FCF too high?
NovoCure's current EV-to-FCF is 0.73. The Medical Devices & Instruments industry median EV-to-FCF is 22.87. NovoCure's value of 0.73 is 96.8% below this industry median. Based on the distribution chart, NovoCure ranks #999999 out of 420 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NovoCure has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's EV-to-FCF compare to NEOG and ESTA?
According to the Medical Devices & Instruments industry distribution chart, NovoCure ranks #999999 out of 420 companies for EV-to-FCF. This places NovoCure in the lower half of its industry. The industry median EV-to-FCF is 22.87. NovoCure's value of 0.73 is 96.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.87, based on 420 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NovoCure's current EV-to-FCF of 0.73 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NovoCure and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovoCure's current EV-to-FCF is 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.98, compared to a current price of R$7.08 — trading 21.2% below its estimated fair value. The current EV-to-FCF is 0.73 and 96.8% below the Medical Devices & Instruments industry median of 22.87. NovoCure's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current EV-to-FCF is 0.73 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovoCure (BSP:N2VC34) Overvalued in 2026?
Based on GuruFocus' analysis, NovoCure stock appears to be undervalued.
The current stock price of R$7.08 is trading 21.2% below its estimated GF Value™ of R$8.98.
GuruFocus considers NovoCure to be Modestly Undervalued.
Key valuation signals for BSP:N2VC34:
EV-to-FCF: 0.73
GF Value™: R$8.98 vs. price of R$7.08 (21.2% below fair value)
Industry Position: 96.8% below the Medical Devices & Instruments median (#999999 of 420)
No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
46GF Score
Get the complete analysis for BSP:N2VC34
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:N2VC34 has been successfully added to your 
